ReviewNature reviews. Cancer2024
Emerging strategies to investigate the biology of early cancer.
Review in Nature reviews. Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- ELISPOT as a Functional for Biomarker Study in Cancer Immunotherapy: Applications and Future Directions.International journal of molecular sciences · 2026Pooled it
- Targeted Chemical Monitoring and Integrated Preclinical Evaluation of Zishui Qinggan Yin in 4-NQO-Induced Esophageal Precancer: Histopathological and PI3K/AKT/mTOR-Associated Changes.Life (Basel, Switzerland) · 2026Article
- Molecular Engineering of AIE Photosensitizers for Enhanced Antitumor Phototheranostics.Advanced healthcare materials · 2026Article
- A dual-view fusion framework using residual gated graph convolution and Mamba for metabolite-disease association prediction with explorations on salivary metabolites.Journal of computer-aided molecular design · 2026Article
- Corynoxine Inhibits Tumor Growth via Targeting NQO1 and Modulating the PTPA-NQO1/PP2A Switch to Activate PP2A.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A high-resolution circulating metabolic atlas of lung adenocarcinoma progression supports early and accurate diagnosis.Cell reports. Medicine · 2026Article
- Folic acid-functionalized polymer dots encapsulating deep red fluorescent carbon nanodots for specific imaging of folate-receptor-positive cancer cells.RSC advances · 2026Article
- A lifespan pooled analysis of 832 cases: characterizing the lifespan profile of clinical presentations and comorbidities in congenital pulmonary airway malformation.Orphanet journal of rare diseases · 2026Article
- CDNFE suggests FNDC3B and NECTIN4 as drivers of precancer progression via PI3K/AKT EMT.NPJ precision oncology · 2026Article
- Single-cell technologies drive mechanistic insights and therapeutic translation in skeletal system research.iScience · 2026Review
- Accelerating discovery of cancer causes for prevention in the era of rising early-onset cancers.Cell · 2026Review
- Lateral flow immunochromatographic assay (LFIA) for tumor marker detection: technical evolution, clinical translation challenges, and future perspectives.Mikrochimica acta · 2026Review
- Article
- Signaling pathways and targeted interventions for precancers.Signal transduction and targeted therapy · 2026Review
- Article
- Integrative bioinformatics and experiments identify RIBC2 as a key regulator in the esophageal cancer.PloS one · 2026Article
- Effects of Common Fig (International journal of molecular sciences · 2025Review
- Plasma untargeted metabolomics reveals the metabolic landscape of NKTCL and aids in liquid biopsy for disease detection.European journal of medical research · 2025Article
- Cell lineage tracing: Methods, applications, and challenges.Quantitative biology (Beijing, China) · 2025Review
- Noninvasive and Sensitive Biosensor for the Detection of Oral Cancer Prognostic Biomarkers.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early detection and intervention of cancer or precancerous lesions hold great promise to improve patient survival. However, the processes of cancer initiation and the normal-precancer-cancer progression within a non-cancerous tissue context remain poorly understood. This is, in part, due to the scarcity of early-stage clinical samples or suitable models to study early cancer. In this Review, we introduce clinical samples and model systems, such as autochthonous mice and organoid-derived or stem cell-derived models that allow longitudinal analysis of early cancer development. We also present the emerging techniques and computational tools that enhance our understanding of cancer initiation and early progression, including direct imaging, lineage tracing, single-cell and spatial multi-omics, and artificial intelligence models. Together, these models and techniques facilitate a more comprehensive understanding of the poorly characterized early malignant transformation cascade, holding great potential to unveil key drivers and early biomarkers for cancer development. Finally, we discuss how these new insights can potentially be translated into mechanism-based strategies for early cancer detection and prevention.
Indexed as
Identifiers
39433978What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.